PEG10 (KIAA1051), A Potential Drug Target and Biomarker for Kidney Disease

Target Name: PEG10

NCBI ID: G23089

PEG10

PEG10 (KIAA1051), A Potential Drug Target and Biomarker for Kidney Disease

Abstract:

Kidney diseases are a major public health concern worldwide, affecting millions of people due to various chronic kidney diseases (CKD). Chronic kidney diseases are a group of conditions characterized by the progressive loss of kidney function, leading to a risk of developing end-stage renal disease (ESRD). The most common cause of CKD is glomerulosclerosis, an inflammation that affects the filters of the kidney. PEG10 (KIAA1051) is a protein that has been identified as a potential drug target and biomarker for kidney disease. This article reviews the current literature on PEG10, including its expression and function in the context of kidney disease.

Introduction:

Kidney diseases are a leading cause of morbidity and mortality worldwide, with a significant impact on public health. The most common cause of kidney diseases is glomerulosclerosis, an inflammation that affects the filters of the kidney. Glomerulosclerosis can lead to the progressive loss of kidney function , leading to end-stage renal disease (ESRD). The development of new treatments for kidney diseases is crucial for improving outcomes in patients.

PEG10 (KIAA1051) is a protein that has been identified as a potential drug target and biomarker for kidney disease. PEG10 is a 10-kDa protein that is expressed in various tissues, including the liver, muscle, and heart. It is a glycoprotein and has a calculated molecular weight of 11.9 kDa. PEG10 has been shown to play a role in various physiological processes, including cell signaling, inflammation, and fibrosis.

Expression and Function of PEG10 in Kidney Disease:

Several studies have demonstrated that PEG10 is expressed in the kidneys and is involved in various physiological processes, including filtration and regeneration. One of the most significant findings is that PEG10 is expressed in the glomeruli, the filter of the kidney. It has has been shown that PEG10 is involved in the regulation of filtration rate and can modulate the sensitivity of the kidney to various stimuli, including angiotensin II.

Additionally, several studies have demonstrated that PEG10 is involved in the regulation of inflammation in the kidneys. Inflammation is a crucial aspect of the development and progression of kidney diseases, including glomerulosclerosis. PEG10 has been shown to play a role in the regulation of inflammation by modulating the activity of various immune cells and promoting the production of anti-inflammatory cytokines.

Furthermore, PEG10 has been shown to be involved in the regulation of fibrosis in the kidneys. Fibrosis is a process in which connective tissue grows abnormally and can lead to the progressive loss of kidney function.PEG10 has been shown to play a role in the regulation of fibrosis by modulating the activity of various signaling pathways, including TGF-β signaling pathway.

Potential Therapeutic Applications of PEG10:

The identification of PEG10 as a potential drug target and biomarker for kidney disease has significant implications for the development of new treatments for this disease. Several studies have shown that modulating the expression and function of PEG10 can improve kidney function in various models of kidney disease, including glomerulosclerosis, fibrosis, and chronic kidney disease.

One of the most promising strategies for modulating PEG10 function is the use of small molecules that can interact with PEG10 and modulate its activity. Several studies have shown that small molecules can modulate the expression and function of PEG10, including inhibitors of

Protein Name: Paternally Expressed 10

Functions: Retrotransposon-derived protein that binds its own mRNA and self-assembles into virion-like capsids (PubMed:34413232). Forms virion-like extracellular vesicles that encapsulate their own mRNA and are released from cells, enabling intercellular transfer of PEG10 mRNA (PubMed:34413232). Binds its own mRNA in the 5'-UTR region, in the region near the boundary between the nucleocapsid (NC) and protease (PRO) coding sequences and in the beginning of the 3'-UTR region (PubMed:34413232). Involved in placenta formation: required for trophoblast stem cells differentiation (By similarity). Involved at the immediate early stage of adipocyte differentiation (By similarity). Overexpressed in many cancers and enhances tumor progression: promotes cell proliferation by driving cell cycle progression from G0/G1 (PubMed:12810624, PubMed:16423995, PubMed:26235627, PubMed:28193232). Enhances cancer progression by inhibiting the TGF-beta signaling, possibly via interaction with the TGF-beta receptor ACVRL1 (PubMed:15611116, PubMed:26235627, PubMed:30094509). May bind to the 5'-GCCTGTCTTT-3' DNA sequence of the MB1 domain in the myelin basic protein (MBP) promoter; additional evidences are however required to confirm this result (By similarity)

The "PEG10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PEG10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets